Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Inducible Fms-like tyrosine kinase 3 ligand (FLT3L) modified cells and application thereof

A tyrosine kinase, cell technology, applied in genetically modified cells, cells modified by introducing foreign genetic material, nucleic acid vectors, etc.

Pending Publication Date: 2020-08-25
上海煦顼技术有限公司
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But CAR-T cells still face chal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inducible Fms-like tyrosine kinase 3 ligand (FLT3L) modified cells and application thereof
  • Inducible Fms-like tyrosine kinase 3 ligand (FLT3L) modified cells and application thereof
  • Inducible Fms-like tyrosine kinase 3 ligand (FLT3L) modified cells and application thereof

Examples

Experimental program
Comparison scheme
Effect test
No Example Login to View More

PUM

No PUM Login to View More

Abstract

The embodiment relates to modified cells for treating a solid tumor, a composition and a method. For example, the composition comprises inducible Fms-like tyrosine kinase 3 ligand (FLT3L) modified cells; the modified cells comprise separated polynucleotide; and the separated polynucleotide comprises polynucleotide of coded FLT3L and polynucleotide of a coded Nuclear Factor of Activated T cells (NFAT) promoter, which is operably connected.

Description

technical field [0001] The present disclosure relates to inducible Fms-related tyrosine kinase 3 ligand-modified cells and uses thereof to treat diseases including cancer. Background technique [0002] With the rapid development of CAR-T technology, CAR-T products targeting tumor-associated antigens (TAA) have been continuously produced. CAR-T cells can accurately target tumor cells, migrate to tumor sites, and be activated by tumor antigens to kill tumor cells. However, CAR-T cells still face challenges in the treatment of solid tumors. Currently, genome editing technologies are able to disrupt gene expression in T cells to enhance effector functions or bypass tumor immunosuppression and metabolically unfavorable tumor microenvironments. Therefore, regulatory T cells are required to address problems associated with solid tumors. Contents of the invention [0003] 1. The problem to be solved [0004] Aiming at the absence of obvious inflammatory response activation in ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/19C07K14/52C12N15/867C12N5/10A61K39/00A61P35/00A61P35/02
CPCA61K39/001112A61K39/001136A61K2039/5156A61P35/00A61P35/02C07K14/52C12N5/0636C12N15/86C12N2510/00C12N2740/15043C12N2800/107
Inventor 沈晓刚孙赫陆诚贾贝贝蒲程飞肖磊
Owner 上海煦顼技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com